摘要:
This invention provides a compound having the formula R.sup.1 --Y.sup.1 --CHZ.sup.1 --CH(NY.sup.2 Y.sup.3)--CH.sub.2 --Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.
摘要翻译:本发明提供具有式R1-Y1-CHZ1-CH(NY2Y3)-CH2-Z2的化合物,其中:R1是在脂族链中具有8至19个碳原子的直链烷基,烯基或炔基; Y1是-CH = CH-,-C3BON或-CH(OH)CH(OH) - ; Z1是OH或转化抑制基团; Z2是转化抑制基团; Y2是H,苯基,在烷基链中具有1至约6个碳的烷基取代的苯基或具有1至6个碳的烷基链; Y 3是H或具有式-C(O)R 2或-S(O)2 R 2的基团; R2是链中具有1至23个碳原子的直链烷基,烯基或炔基; 当Z 2是氨基时,R 2是在脂族链中具有1至9个或19至23个碳原子的脂族链。
摘要:
This invention provides a compound having the formula R.sup.1 -Y.sup.1 --CHZ.sup.1 -CH(NY.sup.2 Y.sup.3)--CH.sub.2 -Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.
摘要翻译:本发明提供具有式R1-Y1-CHZ1-CH(NY2Y3)-CH2-Z2的化合物,其中:R1是在脂族链中具有8至19个碳原子的直链烷基,烯基或炔基; Y1是-CH = CH-,-C3BON或-CH(OH)CH(OH) - ; Z1是OH或转化抑制基团; Z2是转化抑制基团; Y2是H,苯基,在烷基链中具有1至约6个碳的烷基取代的苯基或具有1至6个碳的烷基链; Y 3是H或具有式-C(O)R 2或-S(O)2 R 2的基团; R2是链中具有1至23个碳原子的直链烷基,烯基或炔基; 当Z 2是氨基时,R 2是在脂族链中具有1至9个或19至23个碳原子的脂族链。
摘要:
This invention provides a compound having the formula R.sup.1 --Y.sup.1 --CHZ.sup.1 --CH(NY.sup.2 Y.sup.3)--CH.sub.2 --Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.
摘要翻译:本发明提供具有式R1-Y1-CHZ1-CH(NY2Y3)-CH2-Z2的化合物,其中:R1是在脂族链中具有8至19个碳原子的直链烷基,烯基或炔基; Y1是-CH = CH-,-C3BON或-CH(OH)CH(OH) - ; Z1是OH或转化抑制基团; Z2是转化抑制基团; Y2是H,苯基,在烷基链中具有1至约6个碳的烷基取代的苯基或具有1至6个碳的烷基链; Y 3是H或具有式-C(O)R 2或-S(O)2 R 2的基团; R2是链中具有1至23个碳原子的直链烷基,烯基或炔基; 当Z 2是氨基时,R 2是在脂族链中具有1至9个或19至23个碳原子的脂族链。
摘要:
Provided herein is a taxane having a hydrocarbon attached at the 2′ and/or 7 positions, the hydrocarbon's alpha position being occupied by a “hydrolysis-promoting group” (“HPG”). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the a-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.
摘要:
Provided herein is a taxane having a hydrocarbon attached at the 2' and/or 7 positions, the hydrocarbon's alpha position being occupied by a "hydrolysis-promoting group" ("HPG"). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the .alpha.-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.
摘要:
Provided herein is a taxane having a hydrocarbon attached at the 2′ and/or 7 positions, the hydrocarbon's alpha position being occupied by a “hydrolysis-promoting group” (“HPG”). In one embodiment, the hydrolysis promoting group is stereospecifically attached to the &agr;-carbon of the hydrophobic taxane. The Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers or inflammatory diseases.
摘要:
Described herein are liposomes containing etherlipids of the formula: as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
摘要:
Described herein are methods of preparing liposome-containing pharmaceutical compositions, the liposomes containing headgroup-derivatized lipids and etherlipids having the formula: ##STR1## Such compositions are useful in the treatment of a variety of conditions, including various cancers and inflammatory disorders.
摘要:
Described herein are liposomes containing etherlipids of the formula: ##STR1## as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
摘要:
Liposomes are provided which contain ether lipids having the formula: ##STR1## as well as an underivatized phosphatidylethanolamine, a sterol, and a phosphatidylethanolamine-dicarboxylic acid headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.